Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases

(2009) Johannes Brettschneider et al.   JOURNAL OF NEUROIMMUNOLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

Anti-α-glucose–based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event

(2009) MS Freedman et al.   Multiple Sclerosis Journal

Clinical prognostic factors in multiple sclerosis: a natural history review

(2009) Alexandra Degenhardt et al.   Nature Reviews Neurology

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Induction vs. escalation of therapy for relapsing Multiple Sclerosis: the evidence

(2008) Mark S. Freedman   NEUROLOGICAL SCIENCES